Company: GRCE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001140361-25-041804
Chunk: 13

Company: Grace Therapeutics, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Item 8
Chunk 13
---
 30, 2025

      September 30, 2024

      $ 
      $ 
      $ 
      $ 

      Research and development expenses

      58 
      60 
      127 
      126 

      General and administrative expenses

      148 
      142 
      381 
      314 

      206 
      202 
      508 
      440 

   As of September 30, 2025, there was $516 of total unrecognized compensation cost, related to non-vested stock options, which is expected to be recognized over a remaining weighted-average vesting period of 1.37 years. 

   7. Loss per share

   The Company has generated a net loss for all periods presented. Therefore, diluted loss per share is the same as basic loss per share since the inclusion of potentially dilutive securities would have had an anti-dilutive effect. All currently outstanding options and warrants could potentially be dilutive in the future.
   
   The Company excluded the following potential shares of Common Stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to stockholders for the periods indicated because including them would have had an anti-dilutive effect:  

      Six months ended

      September 30, 2025

      September 30, 2024

      Options outstanding

      1,309,703 
      919,923 

      September 2023 Common Warrants

      2,536,391 
      2,536,391 

      February 2025 Common Warrants

      4,418,291 
       —  

   Basic and diluted net loss per share is calculated based upon the weighted-average number of shares of Common Stock outstanding during the year. Common Stock underlying the 2025 Pre-Funded Warrants and 2023 Pre-Funded Warrants are included in the calculation of basic and diluted earnings per share.

   8. Segment Information

   An operating segment is a component of an entity whose operating results are regularly reviewed by its chief operating decision maker (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance. Factors used by the Company in determining the reportable segment include the nature of the Company's operating activities